PMID- 32414392
OWN - NLM
STAT- MEDLINE
DCOM- 20210125
LR  - 20210125
IS  - 1756-8722 (Electronic)
IS  - 1756-8722 (Linking)
VI  - 13
IP  - 1
DP  - 2020 May 15
TI  - Comparison of haplo-SCT and chemotherapy for young adults with standard-risk 
      Ph-negative acute lymphoblastic leukemia in CR1.
PG  - 52
LID - 10.1186/s13045-020-00879-1 [doi]
LID - 52
AB  - Human leukocyte antigen (HLA) haploidentical stem cell transplantation 
      (haplo-SCT) as a postremission treatment for standard risk Philadelphia 
      chromosome-negative acute lymphoblastic leukemia (SR Ph-ALL) in the first 
      complete remission (CR1) has not been defined. In this multicenter, phase 3 study 
      (NCT02042690), of the 131 consecutive Ph-ALL young adult patients (YA, aged 18-39 
      years) without high-risk features who achieved CR1, 114 patients without 
      HLA-matched donors received consolidation with an adult chemotherapy regimen (n = 
      55) or haplo-SCT (n = 59). In the landmark analysis, haplo-SCT resulted in a 
      lower 2-year cumulative incidence of relapse (CIR, 12.8% vs 46.7%, P = 0.0017) 
      and superior 2-year leukemia-free survival (LFS, 80.9% vs 51.1%, P = 0.0116) and 
      2-year overall survival (OS, 91.2% vs 75.7 [64.8-93.2] %, P = 0.0408) than 
      chemotherapy. In the time-dependent multivariate analysis with propensity score 
      adjustment, postremission treatment (haplo-SCT vs chemotherapy) was an 
      independent risk factor for the CIR (HR 0.195, 95% CI 0.076-0.499, P = 0.001), 
      LFS (HR 0.297, 95% CI 0.131-0.675, P = 0.003), and OS (HR 0.346, 95% CI 
      0.140-0.853, P = 0.011). In all subgroups, CIR was lower in haplo-SCT. 
      Myeloablative haplo-SCT with ATG+G-CSF might be one of the preferred therapies 
      for YA patients with standard-risk Ph-ALL. TRIAL REGISTRATION: 
      ClinicalTrials.gov. Registered on 23 January 2014, 
      https://clinicaltrials.gov/ct2/show/NCT02042690.
FAU - Lv, Meng
AU  - Lv M
AD  - Peking University People's Hospital, Peking University Institute of Hematology, 
      Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National 
      Clinical Research Center for Hematologic Disease, Beijing, China.
FAU - Jiang, Qian
AU  - Jiang Q
AD  - Peking University People's Hospital, Peking University Institute of Hematology, 
      Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National 
      Clinical Research Center for Hematologic Disease, Beijing, China.
FAU - Zhou, Dao-Bin
AU  - Zhou DB
AD  - Peking Union Hospital, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, China.
FAU - Hu, Yu
AU  - Hu Y
AD  - Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and 
      Technology, Wuhan, China.
FAU - Liu, Dai-Hong
AU  - Liu DH
AD  - General Hospital of PLA (People's Liberation Army of China), Beijing, China.
FAU - Wu, De-Pei
AU  - Wu DP
AD  - The First Affiliated Hospital of Soochow University, National Clinical Research 
      Center for Hematologic Disease, Suzhou, China.
FAU - Wang, Jing-Bo
AU  - Wang JB
AD  - Peking University Aerospace Center Hospital, Beijing, China.
FAU - Jiang, Hao
AU  - Jiang H
AD  - Peking University People's Hospital, Peking University Institute of Hematology, 
      Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National 
      Clinical Research Center for Hematologic Disease, Beijing, China.
FAU - Wang, Jing
AU  - Wang J
AD  - Peking University People's Hospital, Peking University Institute of Hematology, 
      Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National 
      Clinical Research Center for Hematologic Disease, Beijing, China.
FAU - Chang, Ying-Jun
AU  - Chang YJ
AD  - Peking University People's Hospital, Peking University Institute of Hematology, 
      Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National 
      Clinical Research Center for Hematologic Disease, Beijing, China.
FAU - Wang, Yu
AU  - Wang Y
AD  - Peking University People's Hospital, Peking University Institute of Hematology, 
      Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National 
      Clinical Research Center for Hematologic Disease, Beijing, China.
FAU - Zhang, Xiao-Hui
AU  - Zhang XH
AD  - Peking University People's Hospital, Peking University Institute of Hematology, 
      Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National 
      Clinical Research Center for Hematologic Disease, Beijing, China.
FAU - Xu, Lan-Ping
AU  - Xu LP
AD  - Peking University People's Hospital, Peking University Institute of Hematology, 
      Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National 
      Clinical Research Center for Hematologic Disease, Beijing, China.
FAU - Liu, Kai-Yan
AU  - Liu KY
AD  - Peking University People's Hospital, Peking University Institute of Hematology, 
      Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National 
      Clinical Research Center for Hematologic Disease, Beijing, China.
FAU - Huang, Xiao-Jun
AU  - Huang XJ
AUID- ORCID: 0000-0002-2145-6643
AD  - Peking University People's Hospital, Peking University Institute of Hematology, 
      Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National 
      Clinical Research Center for Hematologic Disease, Beijing, China. 
      xjhrm@medmail.com.cn.
AD  - Peking-Tsinghua Center for Life Sciences, Beijing, China. xjhrm@medmail.com.cn.
AD  - Research Unit of Key Technique for Diagnosis and Treatments of Hematologic 
      Malignancies (2019RU029), Chinese Academy of Medical Sciences, Beijing, China. 
      xjhrm@medmail.com.cn.
LA  - eng
SI  - ClinicalTrials.gov/NCT02042690
PT  - Clinical Trial, Phase III
PT  - Comparative Study
PT  - Letter
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20200515
PL  - England
TA  - J Hematol Oncol
JT  - Journal of hematology & oncology
JID - 101468937
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antineoplastic Agents/*therapeutic use
MH  - Disease-Free Survival
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Incidence
MH  - Neoplasm Recurrence, Local/diagnosis/etiology
MH  - Philadelphia Chromosome
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy/genetics/*therapy
MH  - Remission Induction
MH  - *Transplantation, Haploidentical
MH  - Young Adult
PMC - PMC7227076
OTO - NOTNLM
OT  - Adult chemotherapy
OT  - Haplo-SCT
OT  - Ph-negative acute lymphoblastic leukemia
COIS- The authors declare that they have no competing interests.
EDAT- 2020/05/18 06:00
MHDA- 2021/01/26 06:00
PMCR- 2020/05/15
CRDT- 2020/05/17 06:00
PHST- 2020/03/11 00:00 [received]
PHST- 2020/04/23 00:00 [accepted]
PHST- 2020/05/17 06:00 [entrez]
PHST- 2020/05/18 06:00 [pubmed]
PHST- 2021/01/26 06:00 [medline]
PHST- 2020/05/15 00:00 [pmc-release]
AID - 10.1186/s13045-020-00879-1 [pii]
AID - 879 [pii]
AID - 10.1186/s13045-020-00879-1 [doi]
PST - epublish
SO  - J Hematol Oncol. 2020 May 15;13(1):52. doi: 10.1186/s13045-020-00879-1.